Bio Pharma Dive

MAY 10, 2021

Laronde comes equipped with $50 million in funding from Flagship Pioneering and a goal to upend how diseases are treated with long-lasting RNA medicines.

RNA 350

RNA Medicine 350

Bio Pharma Dive

JULY 6, 2021

The biotech's decision to pause testing of a cystic fibrosis drug is the latest reminder of the difficulty of delivering RNA medicines into the lungs.

RNA 294

RNA Drugs Medicine 294

Pharmaceutical Technology

MAY 23, 2023

ReNAgade Therapeutics has burst onto the RNA technology scene by announcing a $300m financing round. With its delivery system, Cambridge, Massachusetts-based biotech says it aims to “address major limitations in RNA therapeutics by enabling the delivery of RNA medicines to previously inaccessible tissues and cells in the body.”

RNA 147

RNA Gene Editing Gene Vaccination 147

Pharmaceutical Technology

MARCH 1, 2023

Further, the acceptance of new mRNA vaccines has rejuvenated activity within previously established categories of RNA therapeutics including lifesaving antisense technologies. These include antisense oligonucleotides (ASO), RNA interference (RNAi), and RNA aptamers.

RNA 147

RNA Vaccination Vaccine Genetics 147

Drug Discovery World

APRIL 11, 2023

US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. AI-driven RNA Structure Exploration (PARSE) Atomic AI launched at the start of 2023 with a $35 million series a financing, having previously raised previously raised a $7 million in a seed round.

RNA 52

RNA Medicine Engineer Drugs 52

BioSpace

JUNE 12, 2022

Shape Therapeutics is evolving programmable RNA medicines that push the limits of current gene editing capabilities. BioSpace spoke with CSO David Huss.

Gene Editing 89

Gene Editing RNA Gene Medicine 89

BioSpace

MAY 22, 2023

ReNAgade Launches with $300M to More Easily Deliver RNA Medicines 5/23/2023

RNA 88

RNA Medicine 88

pharmaphorum

NOVEMBER 29, 2023

Japan’s medicines regulator has approved the first vaccine based on self-assembling RNA, a spin on the mRNA technology used in current shots, which is designed to deliver greater efficacy with a lower dose.

RNA 110

RNA Regulation Vaccination Vaccine 110

Bio Pharma Dive

MAY 19, 2023

The biotech, best known for its vaccine research, said its clinical trial is the first to report results of a messenger RNA therapeutic designed for intracellular protein replacement.

RNA 287

RNA Medicine Clinical Trials Clinical Trials 287

Pharmaceutical Technology

OCTOBER 11, 2022

Biotechnology company Ochre Bio has raised $30m in a Series A financing round to develop RNA therapies for chronic liver diseases. It also intends to turn the insights from its research into RNA-based drug candidates, and they will be tested in human livers at the company’s recently opened ‘Liver ICUs’ in the US.

RNA 130

RNA Development Genome Genomics 130

Pharmaceutical Technology

DECEMBER 23, 2022

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. This alliance is utilising the Axiomer ribonucleic acid (RNA) editing platform of ProQR to address ailments affecting the liver and nervous system.

Genetics 328

Genetics Medicine Development Gene Therapy 328

Bio Pharma Dive

JULY 17, 2023

For $500 million, Novartis will acquire DTx Pharma and its preclinical neurological disease drugs, marking the Swiss company’s latest investment in gene-silencing medicines.

Gene Silencing 246

Gene Silencing RNA Drugs Gene 246

Bio Pharma Dive

SEPTEMBER 23, 2022

The British drugmaker decided the medicine, which works similarly to Novartis’s Leqvio, wasn’t potent enough to justify further testing.

RNA 305

RNA Medicine Drugs 305

Bio Pharma Dive

OCTOBER 9, 2023

The agency rejected Alnylam’s application for approval of its medicine patisiran in people with a rare heart condition, setting back the company’s plans.

RNA 156

RNA Drugs Medicine 156

Pharmaceutical Technology

AUGUST 17, 2022

Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs.

RNA 147

RNA Vaccination Vaccine In-Vivo 147

Bio Pharma Dive

MARCH 14, 2023

The company’s name comes from its goal of developing drugs that only “switch” on in target cells, potentially enabling more precise therapies.

RNA 130

RNA Medicine Development Drugs 130

pharmaphorum

NOVEMBER 1, 2022

14th Annual RNA Therapeutics. Investigating the next generation of genetic medicine through RNA based therapies. RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious, and chronic diseases.

RNA 52

RNA Genetics Gene Editing In-Vitro 52

XTalks

SEPTEMBER 13, 2021

With RNA therapies being the next hot thing in genetic medicine, Eli Lilly is joining the RNA editing race by partnering with Netherlands-based ProQR Therapeutics NV (Nasdaq: PRQR), a biotech company developing RNA-based therapies for rare genetic diseases with a focus on blinding disorders of the retina.

RNA 105

RNA Genetics Genetic Disease Medicine 105

Bio Pharma Dive

SEPTEMBER 9, 2021

billion, expands Lilly's work in genetic medicine research. An agreement with the Dutch biotech, which could be worth as much as $1.3

RNA 256

RNA Genetics Medicine Research 256

XTalks

NOVEMBER 9, 2021

Perhaps popularized by the COVID-19 vaccines, RNA-based technologies now have the potential to become the next best pesticide to combat crop pests, like insects and fungal pathogens. Over the last year, researchers have been studying the effectiveness of RNA-based pesticides, and there are already a handful of sprays in the works.

RNA 98

RNA Gene Scientist Protein 98

Medical Xpress

DECEMBER 29, 2022

A clinical research team from the University of Hong Kong (HKUMed) has used amniotic fluid cells obtained during 16-24 weeks of pregnancy as a novel sample type for RNA-sequencing in prenatal diagnosis to help more families with tailored clinical management. The findings have been published in the journal, npj Genomic Medicine.

RNA 75

RNA Genome Genomics Clinical Research 75

Bio Pharma Dive

FEBRUARY 28, 2023

An alliance with the startup brings Vertex an RNA-based medicine for the disease, adding to a portfolio that already includes a gene editing treatment.

Gene Editing 265

Gene Editing RNA Gene Research 265

Drug Discovery World

JANUARY 26, 2023

Atomic AI, a biotechnology company fusing machine learning with structural biology to unlock RNA drug discovery, launched today with a $35 million Series A round. Atomic AI is oriented at the cutting edge of AI, RNA, and structural biology.

RNA 52

RNA Engineer Drugs Medicine 52

Drug Discovery World

FEBRUARY 27, 2023

DDW’s Diana Spencer speaks to Raphael Townshend PhD, Founder and CEO of Atomic AI, about the company’s successes so far, plans for the future and the unique approach of combining RNA structural biology and AI models. DS: How is Atomic AI “unlocking the next generation of RNA drug discovery”? What is unique about your engine?

RNA 52

RNA Engineer Life Science Drugs 52

pharmaphorum

OCTOBER 18, 2021

SMi Group’s 13th Annual Conference: RNA Therapeutics 2022. Bolstering the latest advances and opportunities in RNA-based medicine. Delve into the latest innovations in novel RNA delivery and target specificity. Engage in the growing advances and development of RNA tools for vaccines and anti-infectives. London, UK.

RNA 52

RNA Drug Delivery Scientist Clinical Development 52

BioSpace

JULY 27, 2021

"For the first time in history, medicine has become information." That's the groundbreaking connection AI-driven RNA therapeutics has given us, according to Deep Genomics Founder and CEO Brendan Frey.

RNA 98

RNA Genome Genomics Medicine 98

Bio Pharma Dive

AUGUST 18, 2022

The company plans to soon seek approval of a once-monthly preventive drug for hereditary angioedema, a disease other drugmakers are targeting with gene editing and RNA medicines.

Gene Editing 264

Gene Editing RNA Drugs Gene 264

Bio Pharma Dive

NOVEMBER 29, 2022

In this continuing series, BioPharma Dive examines new areas of biotech investment and startup activity, such as next-generation RNA medicines, TYK2 inhibitors and in vivo CAR-T.

In-Vivo 240

In-Vivo RNA Research Medicine 240

Bio Pharma Dive

NOVEMBER 23, 2021

GSK has secured rights to a genetic medicine in early-stage human testing for NASH, a disease thought to affect millions of people and which has proven to be a tough target for drugmakers.

RNA 177

RNA Genetics Medicine 177

STAT News

NOVEMBER 14, 2022

Ionis Pharmaceuticals, the California company that turned RNA-targeting medicines from an unproven idea into blockbuster drugs, is now expanding into a new class of therapeutics that treat disease by editing DNA.    On Monday, the company announced a partnership with Metagenomi to kickstart these efforts.

Gene Editing 98

Gene Editing RNA Gene Drugs 98

BioTech 365

NOVEMBER 9, 2020

Genialis Harnesses RNA-seq Platform to Advance Precision Medicine Discoveries Genialis Harnesses RNA-seq Platform to Advance Precision Medicine Discoveries New partnerships in oncology R&D, software advances, and the appointment of a new Board member help drive therapeutic breakthroughs SAN RAMON, Calif.–(BUSINESS

RNA 52

RNA Medicine 52

Medical Xpress

MARCH 21, 2023

Researchers at Lund University Faculty of Medicine have determined a novel mechanism linking the metabolism of ribonucleic acids, RNA, to the development of leukemia in myelodysplastic syndrome (MDS) patients.

RNA 72

RNA Regulation Medicine Development 72

pharmaphorum

MAY 11, 2021

Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde , with an ambitious plan to create a new class of drugs based on Endless RNA. Called eRNA for short, this class of medicines is programmable and can continuously express therapeutic proteins inside the body.

RNA 98

RNA Drugs Protein Immune Response 98

Drug Discovery World

JANUARY 10, 2023

This collaboration aims to further exploit circRNAs by developing a novel mechanism to facilitate RNA circularisation specifically in colorectal cancer cells. The post Alliance to develop circular RNA-based therapeutics appeared first on Drug Discovery World (DDW).

RNA 52

RNA Development Gene Therapy Protein 52

Medical Xpress

NOVEMBER 22, 2022

Scientists at University of Florida (UF) Scripps Biomedical Research have developed a potential medicine for a leading cause of ALS and dementia that works by eliminating disease-causing segments of RNA. The compound restored the health of neurons in the lab and rescued mice with the disease.

RNA 76

RNA Scientist Genetics Development 76

Pharma Times

OCTOBER 7, 2021

Leading RNA intereference (RNAi) therapeutics company, Alnylam, has been welcomed as the latest partner in the Medicines Manufacturing Innovation Centre, to transform the manufacturing process of oligonucleotide therapies.

Manufacturing 93

Manufacturing Medicine RNA 93

Drug Discovery World

AUGUST 1, 2023

Investigators at the Icahn School of Medicine at Mount Sinai have designed an RNA-based strategy to activate dendritic cells that eradicated tumours and prevented their recurrence in mouse models of melanoma. The post RNA-based immunotherapy eradicates melanoma tumours appeared first on Drug Discovery World (DDW).

RNA 52

RNA Bioassay Genome Genomics 52